

# **Drug Discovery Technologies Market by Product (Instruments, Reagents, Software), Technology (HTS, NGS, PCR, AI-based, Lab-on-chip), Process (Target Identification, Validation, Lead Optimization), Therapeutic Area (Oncology, CVD) - Global Forecast to 2030**

<https://marketpublishers.com/r/DF4E212B304FEN.html>

Date: January 2026

Pages: 489

Price: US\$ 4,950.00 (Single User License)

ID: DF4E212B304FEN

## **Abstracts**

The drug discovery technologies market is expected to reach USD 51.51 billion in 2030 from USD 30.58 billion in 2025, at a CAGR of 11.0% during the forecast period. The market is driven by the increasing adoption of advanced screening platforms and the shift toward 3D cell cultures, organoids, and organ-on-a-chip models. These technologies improve disease relevance, enhance predictive accuracy, and support more efficient and reliable drug discovery processes. Furthermore, the shift towards targeted and precision therapies further boosts demand. However, high technology costs, complex workflows, and the need for skilled professionals continue to limit market growth.

The in-silico/AI-based drug discovery segment is expected to grow at the highest CAGR during the forecast period.

The in silico/AI-based drug discovery technology segment is growing at the highest CAGR in the drug discovery technologies market due to its ability to shorten discovery timelines, reduce costs, and improve success rates. These technologies use computational modeling, machine learning, and data analytics to rapidly identify and optimize drug candidates. By analyzing large biological and chemical datasets, AI-based platforms enable accurate target identification, lead screening, and toxicity prediction at early stages. This reduces reliance on trial-and-error laboratory methods

and minimizes late-stage failures. Their scalability, speed, and ability to support precision medicine make in silico and AI-based technologies essential tools for pharmaceutical and biotechnology companies, driving strong adoption across the market.

The oncology segment holds the largest share of the market.

The oncology segment accounts for the largest share of the Drug Discovery Technologies Market. This growth is driven by the increasing prevalence of cancer worldwide and the rising focus on developing targeted and personalized therapies. Advanced screening platforms, high-throughput assays, and cell-based models are widely used to identify potential drug candidates, validate targets, and optimize leads. Strong investments in cancer research, expanding clinical pipelines, and growing collaboration between pharmaceutical companies and research institutes further support the adoption of these technologies. Improved drug development efficiency and the demand for more effective cancer treatments continue to drive growth in this segment globally.

The US is expected to grow at the highest CAGR during the forecast period.

The US is experiencing the highest growth in the drug discovery technologies market due to several factors. A strong presence of leading pharmaceutical and biotech companies, advanced research infrastructure, and a large number of ongoing oncology programs are key drivers. Increasing adoption of high-throughput screening, 3D cell models, and organ-on-a-chip platforms in cancer research is fueling demand. Supportive regulations, substantial public and private funding for biomedical research, and a focus on precision medicine further contribute to market expansion. Widespread use of advanced discovery technologies and robust collaborations between industry and research institutes enhance innovation, ensuring high-quality outputs and reinforcing North America's leading position globally.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side – 70% and Demand Side– 30%

By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25%

By Region: North America – 40%, Europe – 25%, Asia Pacific – 25%, Latin

America – 5%, the Middle East & Africa – 5%

Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), F. Hoffmann-La Roche Ltd (Switzerland), Bruker (US), QIAGEN (Germany), Bio-Rad Laboratories, Inc. (US), Tecan Trading AG (Switzerland), Takara Bio Inc. (Japan), Corning Incorporated (US), Hamilton Company (US), PacBio (US), Oxford Nanopore Technologies plc (UK), Promega Corporation (US), Waters Corporation (US), Merck KGAA (Germany), Sartorius AG (Germany), BD (US), Eppendorf SE (Germany), Shimadzu Corporation (Japan), Aurora Biomed Inc. (Canada), Standard BioTools (US), Jeol Ltd. (Japan), Gilson Incorporated (US), BIOMERIEUX (France), Greiner AG (Austria), BGI Group (China), Porvair (UK), Polaris Genomics (US), BICO (Sweden), Creative Bioarray (US), Sphere Bio (UK), GenScript (UK), Schrödinger, Inc. (US), LECO Corporation (US), TransGen Biotech Co., Ltd. (China), BMG LABTECH (Germany), NanoTemper Technologies (Germany), MGI Tech Co., Ltd. (China), Araceli Biosciences (US), Sphere Bio (US), BioSolveIT GmbH (Germany), and Evosep (Denmark) are some of the key companies offering drug discovery technologies products.

## Research Coverage

This research report categorizes the drug discovery technologies market by product (reagents & consumables, instruments, bioinformatics tools & software), technology (high-throughput screening technologies, next-generation sequencing, polymerase chain reaction, in-silico/AI-based drug discovery technologies, X-ray crystallography, chromatography, mass spectrometry, other technologies), process (target identification, target validation, hit-to-lead identification, lead optimization, candidate validation), therapeutic area (oncology, infectious diseases, cardiovascular diseases, neurological diseases, endocrine & metabolic diseases, autoimmune disorders, other therapeutic areas), end user (pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CROs), other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa).

The report's scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the drug discovery technologies market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the drug discovery technologies market. This report also includes a

competitive analysis of emerging startups in the drug discovery technologies industry ecosystem.

### **Key Benefits of Buying the Report**

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market's pulse and offer information on key market drivers, restraints, opportunities, and challenges.

### **The report provides insights into the following pointers:**

Analysis of key drivers (increasing adoption of advanced screening platforms, shift toward biologics and advanced therapeutic modalities, transition from conventional two-dimensional cultures to three-dimension models, technological innovations in assay miniaturization and automation), restraints (high up-front investment in instruments, automation, and data infrastructure and shortage of skilled personnel), opportunities (growing demand for in-silico based discovery and increasing need for specialized ADME/Toxicology testing), and challenges (assay reproducibility and standardization issues) influencing the market growth

**Product Development/Innovation:** Detailed insights into newly launched products and technological assessment of the drug discovery technologies market

**Market Development:** Comprehensive information about lucrative markets and analysis of the market across varied regions

**Market Diversification:** Exhaustive information about new products, untapped geographies, recent developments, and investments in the drug discovery technologies market

**Competitive Assessment:** In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), among others, offering products for the drug discovery technologies market. Other companies include Polaris Genomics (US), BICO (Sweden), Creative Bioarray (US), Sphere Bio (UK), GenScript

(UK), Schrödinger, Inc. (US), LECO Corporation (US), among others, for the drug discovery technologies market.

## Contents

### 1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
  - 1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
  - 1.3.2 INCLUSIONS AND EXCLUSIONS
  - 1.3.3 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 SUMMARY OF CHANGES

### 2 EXECUTIVE SUMMARY

- 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
- 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS IN DRUG DISCOVERY TECHNOLOGIES MARKET
- 2.4 HIGH-GROWTH SEGMENTS
- 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

### 3 PREMIUM INSIGHTS

- 3.1 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT
- 3.2 DRUG DISCOVERY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- 3.3 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2025 VS. 2030 (%)

### 4 MARKET OVERVIEW

- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
  - 4.2.1 DRIVERS
    - 4.2.1.1 Increasing adoption of advanced screening platforms
    - 4.2.1.2 Shift toward biologics and advanced therapeutic modalities
    - 4.2.1.3 Transition from conventional two-dimensional cultures to three-dimensional

## models

4.2.1.4 Technological innovations in assay miniaturization and automation

### 4.2.2 RESTRAINTS

4.2.2.1 High up-front investment in instruments, automation, and data infrastructure

4.2.2.2 Shortage of skilled personnel

### 4.2.3 OPPORTUNITIES

4.2.3.1 Growing demand for in-silico-based discovery

4.2.3.2 Increasing need for specialized ADME/Toxicology testing

### 4.2.4 CHALLENGES

4.2.4.1 Assay reproducibility and standardization issues

## 4.3 UNMET NEEDS AND WHITE SPACES

## 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES

## 4.5 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS

## 5 INDUSTRY TRENDS

### 5.1 PORTER'S FIVE FORCES ANALYSIS

5.1.1 INTENSITY OF COMPETITIVE RIVALRY

5.1.2 BARGAINING POWER OF SUPPLIERS

5.1.3 BARGAINING POWER OF BUYERS

5.1.4 THREAT OF SUBSTITUTES

5.1.5 THREAT OF NEW ENTRANTS

### 5.2 MACROECONOMIC OUTLOOK

5.2.1 INTRODUCTION

5.2.2 GDP TRENDS AND FORECAST

5.2.3 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY

5.2.4 R&D TRENDS IN GLOBAL PHARMA INDUSTRY

### 5.3 VALUE CHAIN ANALYSIS

### 5.4 ECOSYSTEM ANALYSIS

### 5.5 PRICING ANALYSIS

5.5.1 AVERAGE SELLING PRICE OF END USERS, BY KEY PLAYER, 2024

5.5.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024

5.5.2.1 Average selling price of instruments, by key player, 2024

5.5.2.2 Average selling price of consumables, by key player, 2024

5.5.3 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2022–2024

5.5.4 AVERAGE SELLING PRICE TREND, BY REGION, 2022–2024

### 5.6 TRADE ANALYSIS

5.6.1 IMPORT SCENARIO FOR HS CODE 3822.00

- 5.6.2 EXPORT SCENARIO FOR HS CODE 3822.00
- 5.6.3 IMPORT SCENARIO FOR HS CODE 9027.00
- 5.6.4 EXPORT SCENARIO FOR HS CODE 9027.00
- 5.7 KEY CONFERENCES AND EVENTS, 2025–2026
- 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.9 INVESTMENT AND FUNDING SCENARIO
- 5.10 CASE STUDY ANALYSIS
  - 5.10.1 AI-DESIGNED IPF DRUG CANDIDATE ADVANCES IN CLINICAL DEVELOPMENT
  - 5.10.2 INDUSTRY CONSORTIUM POOLS DATA TO IMPROVE AI-DRIVEN SMALL MOLECULE DISCOVERY
  - 5.10.3 NEW AI FRAMEWORK FROM IIT MADRAS AND OHIO STATE STREAMLINES MOLECULAR DESIGN
- 5.11 IMPACT OF 2025 US TARIFF ON DRUG DISCOVERY TECHNOLOGIES MARKET
  - 5.11.1 INTRODUCTION
  - 5.11.2 KEY TARIFF RATES
  - 5.11.3 PRICE IMPACT ANALYSIS
  - 5.11.4 KEY IMPACT ON COUNTRIES/REGIONS
    - 5.11.4.1 US
    - 5.11.4.2 Europe
    - 5.11.4.3 Asia Pacific
  - 5.11.5 END-USE INDUSTRY IMPACT
    - 5.11.5.1 Pharmaceutical and Biotechnology Companies
    - 5.11.5.2 Academic and Research Institutes
    - 5.11.5.3 Contract Research Organizations (CROs)

## **6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS**

- 6.1 KEY EMERGING TECHNOLOGIES
  - 6.1.1 HIGH-THROUGHPUT SCREENING (HTS) & AUTOMATION
  - 6.1.2 AUTOMATED LIQUID HANDLING
- 6.2 ADJACENT TECHNOLOGIES
  - 6.2.1 AI/ML-ENABLED & IN SILICO DISCOVERY PLATFORMS
  - 6.2.2 DISCOVERY INFORMATICS & LAB DIGITALIZATION
- 6.3 TECHNOLOGY/PRODUCT ROADMAP
- 6.4 PATENT ANALYSIS
  - 6.4.1 METHODOLOGY

6.4.2 NUMBER OF PATENTS FILED

6.4.3 LIST OF KEY PATENTS

6.5 FUTURE APPLICATIONS

6.6 IMPACT OF AI/GEN AI ON DRUG DISCOVERY TECHNOLOGIES MARKET

6.6.1 TOP USE CASES AND MARKET POTENTIAL

6.6.2 BEST PRACTICES IN AI-ENABLED DRUG DISCOVERY WORKFLOWS

6.6.3 CASE STUDIES OF AI IMPLEMENTATION IN DRUG DISCOVERY

TECHNOLOGIES MARKET

6.6.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS

6.6.5 CLIENTS' READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN IN DRUG DISCOVERY TECHNOLOGIES MARKET

## **7 SUSTAINABILITY AND REGULATORY LANDSCAPE**

7.1 REGIONAL REGULATIONS AND COMPLIANCE

7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

7.1.2 INDUSTRY STANDARDS

7.1.2.1 North America

7.1.2.1.1 US

7.1.2.1.2 Canada

7.1.2.2 Europe

7.1.2.2.1 UK

7.1.2.3 Asia Pacific

7.1.2.3.1 China

7.1.2.3.2 Japan

7.1.2.3.3 India

7.1.2.3.4 South Korea

7.1.2.3.5 Australia

7.1.2.3.6 Rest of Asia Pacific

7.2 SUSTAINABILITY INITIATIVES

7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES

7.4 CERTIFICATIONS, LABELING, ECO-STANDARDS

## **8 CUSTOMER LANDSCAPE & BUYER BEHAVIOUR**

8.1 DECISION-MAKING PROCESS

8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA

- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 KEY BUYING CRITERIA, BY END USER
- 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

## **9 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT**

- 9.1 INTRODUCTION
- 9.2 REAGENTS & CONSUMABLES
  - 9.2.1 INNOVATIONS IN ASSAY CHEMISTRY AND SUPPLY CHAIN RESILIENCE TO PROMOTE GROWTH
- 9.3 INSTRUMENTS
  - 9.3.1 HIGH-PERFORMANCE ANALYTICAL ATTRIBUTES AND AUTOMATION TO DRIVE MARKET
- 9.4 BIOINFORMATICS TOOLS & SOFTWARE
  - 9.4.1 AI RISING ADOPTION OF AI AND MACHINE LEARNING FOR PREDICTIVE MODELING TO FUEL MARKET

## **10 DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY**

- 10.1 INTRODUCTION
- 10.2 HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES
  - 10.2.1 AUTOMATED LIQUID HANDLING
    - 10.2.1.1 Increasing focus on precision, integration, and productivity to drive market
  - 10.2.2 MICROPLATE-BASED HTS
    - 10.2.2.1 Rising investments in pharmaceutical and biotechnology R&D to fuel market
  - 10.2.3 LAB-ON-A CHIP
    - 10.2.3.1 Increasing demand for more predictive preclinical models to boost market
  - 10.2.4 LABEL-FREE TECHNOLOGY
    - 10.2.4.1 Real-time, label-free interaction to accelerate segment growth
- 10.3 NEXT-GENERATION SEQUENCING
  - 10.3.1 EXPANDED INTEGRATION OF ADVANCED NGS TECHNOLOGIES TO DRIVE MARKET
- 10.4 POLYMERASE CHAIN REACTION
  - 10.4.1 ENHANCED POLYMERASE CHAIN REACTION INNOVATION AND AUTOMATION TO DRIVE MARKET
- 10.5 IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES
  - 10.5.1 COMPUTATIONAL INTELLIGENCE AND COLLABORATIVE AI INNOVATIONS TO PROPEL MARKET

## 10.6 X-RAY CRYSTALLOGRAPHY

10.6.1 ADVANCED INSTRUMENTATION AND INNOVATIVE X-RAY TECHNIQUES TO BOOST MARKET

## 10.7 CHROMATOGRAPHY

10.7.1 REGULATORY PRESSURES AND COMPLEX BIOLOGICS R&D TO AID GROWTH

## 10.8 MASS SPECTROMETRY

10.8.1 INVESTMENT IN ADVANCED INSTRUMENTATION AND DATA-DRIVEN WORKFLOWS TO DRIVE MARKET

## 10.9 OTHER TECHNOLOGIES

# 11 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS

## 11.1 INTRODUCTION

### 11.2 TARGET IDENTIFICATION

11.2.1 INCREASING CLINICAL DATA VOLUME TO BOOST MARKET

### 11.3 TARGET VALIDATION

11.3.1 INCREASING TECHNOLOGICAL ADVANCEMENTS TO PROMOTE GROWTH

### 11.4 HIT-TO-LEAD IDENTIFICATION

11.4.1 GROWING ADOPTION OF MULTI-DISCIPLINARY APPROACHES TO DRIVE MARKET

### 11.5 LEAD OPTIMIZATION

11.5.1 INCREASING FOCUS ON REDUCING LATE-STAGE ATTRITION AND INCREASING PROBABILITY OF THERAPEUTIC SUCCESS TO FUEL MARKET

### 11.6 CANDIDATE VALIDATION

11.6.1 INCREASING COMPLEXITY OF THERAPEUTIC MODALITIES TO SUSTAIN GROWTH

# 12 DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA

## 12.1 INTRODUCTION

### 12.2 ONCOLOGY

12.2.1 SHIFT TOWARD PRECISION ONCOLOGY TO PROMOTE GROWTH

### 12.3 INFECTIOUS DISEASES

12.3.1 RISING ANTIMICROBIAL RESISTANCE AND AI-DRIVEN INNOVATIONS TO DRIVE MARKET

### 12.4 CARDIOVASCULAR DISEASES

12.4.1 INCREASING PREVALENCE OF CARDIOVASCULAR RISK FACTORS TO

## BOOST MARKET

### 12.5 NEUROLOGICAL DISEASES

12.5.1 INTEGRATION OF ADVANCED MODELS AND STRATEGIC INVESTMENTS TO FUEL MARKET

### 12.6 ENDOCRINE & METABOLIC DISORDERS

12.6.1 RISING PREVALENCE OF TYPE 2 DIABETES, OBESITY, AND ASSOCIATED METABOLIC SYNDROMES TO DRIVE MARKET

### 12.7 AUTOIMMUNE DISORDERS

12.7.1 WIDESPREAD ADOPTION OF BIOLOGICS AND SMALL MOLECULES TO PROPEL MARKET

### 12.8 OTHER THERAPEUTIC AREAS

## **13 DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER**

### 13.1 INTRODUCTION

#### 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

13.2.1 TECHNOLOGY INTEGRATION AND STRATEGIC PARTNERSHIPS TO CONTRIBUTE TO GROWTH

#### 13.3 ACADEMIC & RESEARCH INSTITUTES

13.3.1 RISING PUBLIC AND PRIVATE RESEARCH FUNDING AND STRONGER ACADEMIC-INDUSTRY COLLABORATION FRAMEWORKS TO AUGMENT GROWTH

#### 13.4 CONTRACT RESEARCH ORGANIZATIONS (CRO)

13.4.1 INCREASING R&D OUTSOURCING TO EXPEDITE GROWTH

## **14 DRUG DISCOVERY TECHNOLOGIES MARKET, BY REGION**

### 14.1 INTRODUCTION

#### 14.2 NORTH AMERICA

##### 14.2.1 US

14.2.1.1 Expanding network of cross-border partnerships and investments to expedite growth

##### 14.2.2 CANADA

14.2.2.1 Increasing adoption of AI and open-science models to accelerate growth

#### 14.3 EUROPE

##### 14.3.1 GERMANY

14.3.1.1 Strong network of publicly funded research institutes, contract research organizations, and pharmaceutical developers to boost market

##### 14.3.2 UK

14.3.2.1 Increasing focus on next-generation computational platforms to promote growth

#### 14.3.3 FRANCE

14.3.3.1 Robust innovation ecosystem and AI-enabled research to propel market

#### 14.3.4 ITALY

14.3.4.1 Rising research funding to contribute to growth

#### 14.3.5 SPAIN

14.3.5.1 Well-established network of research centers and universities to boost market

#### 14.3.6 REST OF EUROPE

### 14.4 ASIA PACIFIC

#### 14.4.1 CHINA

14.4.1.1 Global partnerships to propel market

#### 14.4.2 JAPAN

14.4.2.1 Rising integration of AI and international partnerships to favor growth

#### 14.4.3 INDIA

14.4.3.1 Domestic infrastructure enhancements and government initiatives to support growth

#### 14.4.4 AUSTRALIA

14.4.4.1 Rising adoption of artificial intelligence and advanced computational tools to foster growth

#### 14.4.5 SOUTH KOREA

14.4.5.1 Favorable public policies to support growth

#### 14.4.6 REST OF ASIA PACIFIC

### 14.5 LATIN AMERICA

#### 14.5.1 BRAZIL

14.5.1.1 Public-private collaborations to bolster growth

#### 14.5.2 MEXICO

14.5.2.1 Rising demand for AI-powered research to support growth

#### 14.5.3 REST OF LATIN AMERICA

### 14.6 MIDDLE EAST

#### 14.6.1 GCC COUNTRIES

##### 14.6.1.1 Saudi Arabia

14.6.1.1.1 Increasing focus on regulatory reform, research funding, and international partnerships to boost market

##### 14.6.1.2 UAE

14.6.1.2.1 Strong government vision and cross-sector partnerships to aid growth

##### 14.6.1.3 Rest of GCC countries

#### 14.6.2 REST OF MIDDLE EAST

## 14.7 AFRICA

### 14.7.1 STRATEGIC PARTNERSHIPS AND CAPACITY BUILDING INITIATIVES TO PROPEL MARKET

## 15 COMPETITIVE LANDSCAPE

### 15.1 OVERVIEW

### 15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN

### 15.3 REVENUE ANALYSIS

### 15.4 MARKET SHARE ANALYSIS

### 15.5 BRAND/PRODUCT COMPARISON

#### 15.5.1 THERMO FISHER SCIENTIFIC INC.

#### 15.5.2 MERCK KGAA

#### 15.5.3 AGILENT TECHNOLOGIES, INC.

#### 15.5.4 REVVITY

#### 15.5.5 ILLUMINA, INC.

### 15.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024

#### 15.6.1 STARS

#### 15.6.2 EMERGING LEADERS

#### 15.6.3 PERVASIVE PLAYERS

#### 15.6.4 PARTICIPANTS

#### 15.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024

##### 15.6.5.1 Company footprint

##### 15.6.5.2 Region footprint

##### 15.6.5.3 Product footprint

##### 15.6.5.4 Technology footprint

##### 15.6.5.5 Process footprint

### 15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024

#### 15.7.1 PROGRESSIVE COMPANIES

#### 15.7.2 RESPONSIVE COMPANIES

#### 15.7.3 DYNAMIC COMPANIES

#### 15.7.4 STARTING BLOCKS

#### 15.7.5 COMPETITIVE BENCHMARKING

##### 15.7.5.1 Detailed list of key startups/SMEs

##### 15.7.5.2 Competitive benchmarking of key startups/SMEs

### 15.8 COMPANY VALUATION AND FINANCIAL METRICS

### 15.9 COMPETITIVE SCENARIO

#### 15.9.1 PRODUCT LAUNCHES

#### 15.9.2 DEALS

15.9.3 EXPANSIONS

15.9.4 OTHER DEVELOPMENTS

## **16 COMPANY PROFILES**

### **16.1 KEY PLAYERS**

#### **16.1.1 THERMO FISHER SCIENTIFIC INC.**

16.1.1.1 Business overview

16.1.1.2 Products offered

16.1.1.3 Recent developments

16.1.1.3.1 Product launches

16.1.1.3.2 Deals

16.1.1.3.3 Expansions

16.1.1.4 MnM view

16.1.1.4.1 Key strengths/Right to win

16.1.1.4.2 Strategic choices

16.1.1.4.3 Weaknesses/Competitive threats

#### **16.1.2 MERCK KGAA**

16.1.2.1 Business overview

16.1.2.2 Products offered

16.1.2.3 Recent developments

16.1.2.3.1 Deals

16.1.2.3.2 Expansions

16.1.2.4 MnM view

16.1.2.4.1 Key strengths/Right to win

16.1.2.4.2 Strategic choices

16.1.2.4.3 Weaknesses/Competitive threats

#### **16.1.3 AGILENT TECHNOLOGIES, INC.**

16.1.3.1 Business overview

16.1.3.2 Products offered

16.1.3.3 Recent developments

16.1.3.3.1 Product launches

16.1.3.3.2 Expansions

16.1.3.4 MnM view

16.1.3.4.1 Key strengths/Right to win

16.1.3.4.2 Strategic choices

16.1.3.4.3 Weaknesses/Competitive threats

#### **16.1.4 REVVITY**

16.1.4.1 Business overview

- 16.1.4.2 Products offered
- 16.1.4.3 Recent developments
  - 16.1.4.3.1 Product launches
  - 16.1.4.3.2 Deals
  - 16.1.4.3.3 Expansions
- 16.1.4.4 MnM view
  - 16.1.4.4.1 Key strengths/Right to win
  - 16.1.4.4.2 Strategic choices
  - 16.1.4.4.3 Weaknesses/Competitive threats
- 16.1.5 ILLUMINA, INC.
  - 16.1.5.1 Business overview
  - 16.1.5.2 Products offered
  - 16.1.5.3 Recent developments
    - 16.1.5.3.1 Product launches
    - 16.1.5.3.2 Deals
    - 16.1.5.3.3 Expansions
    - 16.1.5.3.4 Other developments
  - 16.1.5.4 MnM view
    - 16.1.5.4.1 Key strengths/Right to win
    - 16.1.5.4.2 Strategic choices
    - 16.1.5.4.3 Weaknesses/Competitive threats
- 16.1.6 DANAHER CORPORATION
  - 16.1.6.1 Business overview
  - 16.1.6.2 Products offered
  - 16.1.6.3 Recent developments
    - 16.1.6.3.1 Product launches
    - 16.1.6.3.2 Deals
    - 16.1.6.3.3 Expansions
  - 16.1.6.4 MnM view
    - 16.1.6.4.1 Key strengths/Right to win
    - 16.1.6.4.2 Strategic choices
    - 16.1.6.4.3 Weaknesses/Competitive threats
- 16.1.7 F. HOFFMANN-LA ROCHE LTD
  - 16.1.7.1 Business overview
  - 16.1.7.2 Products offered
  - 16.1.7.3 Recent developments
    - 16.1.7.3.1 Product launches
    - 16.1.7.3.2 Deals
    - 16.1.7.3.3 Other developments

**16.1.8 BRUKER**

- 16.1.8.1 Business overview
- 16.1.8.2 Products offered
- 16.1.8.3 Recent developments
  - 16.1.8.3.1 Product launches
  - 16.1.8.3.2 Deals
  - 16.1.8.3.3 Expansions

**16.1.9 QIAGEN**

- 16.1.9.1 Business overview
- 16.1.9.2 Products offered
- 16.1.9.3 Recent developments
  - 16.1.9.3.1 Product launches
  - 16.1.9.3.2 Deals
  - 16.1.9.3.3 Expansions

**16.1.10 BIO-RAD LABORATORIES, INC.**

- 16.1.10.1 Business overview
- 16.1.10.2 Products offered
- 16.1.10.3 Recent developments
  - 16.1.10.3.1 Product launches
  - 16.1.10.3.2 Deals

**16.1.11 TECAN TRADING AG**

- 16.1.11.1 Business overview
- 16.1.11.2 Products offered

**16.1.12 TAKARA BIO INC.**

- 16.1.12.1 Business overview
- 16.1.12.2 Products offered
- 16.1.12.3 Recent developments
  - 16.1.12.3.1 Product launches

**16.1.13 CORNING INCORPORATED**

- 16.1.13.1 Business overview
- 16.1.13.2 Products offered

**16.1.14 HAMILTON COMPANY**

- 16.1.14.1 Business overview
- 16.1.14.2 Products offered
- 16.1.14.3 Recent developments
  - 16.1.14.3.1 Product launches
  - 16.1.14.3.2 Deals

**16.1.15 PACBIO**

- 16.1.15.1 Business overview

- 16.1.15.2 Products offered
- 16.1.15.3 Recent developments
  - 16.1.15.3.1 Product launches
  - 16.1.15.3.2 Expansions
- 16.1.16 OXFORD NANOPORE TECHNOLOGIES PLC
  - 16.1.16.1 Business overview
  - 16.1.16.2 Products offered
  - 16.1.16.3 Recent developments
    - 16.1.16.3.1 Product launches
    - 16.1.16.3.2 Deals
- 16.1.17 PROMEGA CORPORATION
  - 16.1.17.1 Business overview
  - 16.1.17.2 Products offered
- 16.1.18 WATERS CORPORATION
  - 16.1.18.1 Business overview
  - 16.1.18.2 Products offered
  - 16.1.18.3 Recent developments
    - 16.1.18.3.1 Product launches
    - 16.1.18.3.2 Deals
- 16.1.19 SARTORIUS AG
  - 16.1.19.1 Business overview
  - 16.1.19.2 Products offered
  - 16.1.19.3 Recent developments
    - 16.1.19.3.1 Deals
- 16.1.20 BD
  - 16.1.20.1 Business overview
  - 16.1.20.2 Products offered
  - 16.1.20.3 Recent developments
    - 16.1.20.3.1 Product launches
    - 16.1.20.3.2 Deals
- 16.1.21 EPPENDORF SE
  - 16.1.21.1 Business overview
  - 16.1.21.2 Products offered
  - 16.1.21.3 Recent developments
    - 16.1.21.3.1 Deals
- 16.1.22 SHIMADZU CORPORATION
  - 16.1.22.1 Business overview
  - 16.1.22.2 Business overview
  - 16.1.22.3 Products offered

- 16.1.23 AURORA BIOMED INC.
  - 16.1.23.1 Business overview
  - 16.1.23.2 Products offered
- 16.1.24 STANDARD BIOTOOLS
  - 16.1.24.1 Business overview
  - 16.1.24.2 Products offered
- 16.1.25 JEOL LTD.
  - 16.1.25.1 Business overview
  - 16.1.25.2 Products offered
- 16.1.26 GILSON INCORPORATED
  - 16.1.26.1 Business overview
  - 16.1.26.2 Products offered
- 16.1.27 BIOM?RIEUX
  - 16.1.27.1 Business overview
  - 16.1.27.2 Products offered
- 16.1.28 GREINER AG
  - 16.1.28.1 Business overview
  - 16.1.28.2 Products offered
- 16.1.29 BGI GROUP
  - 16.1.29.1 Business overview
  - 16.1.29.2 Products offered
- 16.1.30 PORVAIR
  - 16.1.30.1 Business overview
  - 16.1.30.2 Products offered
- 16.2 OTHER PLAYERS
  - 16.2.1 POLARIS GENOMICS
  - 16.2.2 BICO
  - 16.2.3 CREATIVE BIOARRAY
  - 16.2.4 SPHERE BIO
  - 16.2.5 GENSCRIPT
  - 16.2.6 SCHR?DINGER, INC.
  - 16.2.7 LECO CORPORATION
  - 16.2.8 TRANSGEN BIOTECH CO., LTD
  - 16.2.9 BMG LABTECH
  - 16.2.10 NANOTEMPER TECHNOLOGIES
  - 16.2.11 MGI TECH CO., LTD.
  - 16.2.12 ARACELI BIOSCIENCES
  - 16.2.13 ANALYTIK JENA GMBH+CO. KG
  - 16.2.14 BIOSOLVEIT GMBH

16.2.15 EVOSEP

## **17 RESEARCH METHODOLOGY**

17.1 RESEARCH DATA

17.1.1 SECONDARY DATA

17.1.1.1 Key data from secondary sources

17.1.2 PRIMARY DATA

17.1.2.1 Key data from primary sources

17.1.2.2 Key primary participants

17.1.2.3 Breakdown of primary interviews

17.1.2.4 Key industry insights

17.2 MARKET SIZE ESTIMATION

17.2.1 BOTTOM-UP APPROACH

17.2.2 TOP-DOWN APPROACH

17.2.3 BASE NUMBER CALCULATION

17.3 GROWTH FORECAST MODEL

17.4 DATA TRIANGULATION

17.5 FACTOR ANALYSIS

17.6 RESEARCH ASSUMPTIONS

17.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT

## **18 APPENDIX**

18.1 DISCUSSION GUIDE

18.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

18.3 CUSTOMIZATION OPTIONS

18.4 RELATED REPORTS

18.5 AUTHOR DETAILS

## List Of Tables

### LIST OF TABLES

TABLE 1 DRUG DISCOVERY TECHNOLOGIES MARKET: INCLUSIONS AND EXCLUSIONS

TABLE 2 DRUG DISCOVERY TECHNOLOGIES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS

TABLE 3 DRUG DISCOVERY TECHNOLOGIES MARKET: PORTER'S FIVE FORCES

TABLE 4 DRUG DISCOVERY TECHNOLOGIES MARKET: ROLE OF COMPANIES IN ECOSYSTEM

TABLE 5 AVERAGE SELLING PRICE OF END USERS, BY KEY PLAYERS, 2024

TABLE 6 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024 (USD MILLION)

TABLE 7 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2022–2024

TABLE 8 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2022–2024 (USD MILLION)

TABLE 9 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY REGION, 2022–2024 (USD MILLION)

TABLE 10 IMPORT DATA FOR HS CODE 3822.00, BY COUNTRY, 2020–2024 (USD THOUSAND)

TABLE 11 EXPORT DATA FOR HS CODE 3822.00, BY COUNTRY, 2020–2024 (USD THOUSAND)

TABLE 12 IMPORT DATA FOR HS CODE 9027.00, BY COUNTRY, 2020–2024 (USD THOUSAND)

TABLE 13 EXPORT DATA FOR HS CODE 9027.00, BY COUNTRY, 2020–2024 (USD THOUSAND)

TABLE 14 DRUG DISCOVERY TECHNOLOGIES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026

TABLE 15 US ADJUSTED RECIPROCAL TARIFF RATES

TABLE 16 KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT TO DRUG DISCOVERY TECHNOLOGIES

TABLE 17 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES

TABLE 18 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024

TABLE 19 LIST OF KEY PATENTS IN DRUG DISCOVERY TECHNOLOGIES MARKET, 2023–2025

TABLE 20 CASE STUDIES OF AI IMPLEMENTATION IN DRUG DISCOVERY TECHNOLOGIES MARKET

TABLE 21 CLIENT'S READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN IN DRUG DISCOVERY TECHNOLOGIES MARKET

TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 25 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 26 DRUG DISCOVERY TECHNOLOGIES MARKET: VENDOR CERTIFICATIONS

TABLE 27 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT

TABLE 28 KEY BUYING CRITERIA, BY END USER

TABLE 29 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 30 DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2023–2030 (USD MILLION)

TABLE 31 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 32 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 33 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 34 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 35 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2023–2030 (USD MILLION)

TABLE 36 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 37 DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 38 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 39 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 40 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 41 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 42 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 43 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 44 DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY REGION, 2023–2030 (USD MILLION)

TABLE 45 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 46 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 47 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 48 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 49 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY REGION, 2023–2030 (USD MILLION)

TABLE 50 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 51 DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 52 DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 53 DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 54 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 55 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 56 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030

(USD MILLION)

TABLE 57 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 58 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 59 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 60 DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY REGION, 2023–2030 (USD MILLION)

TABLE 61 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 62 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 63 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 64 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 65 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY REGION, 2023–2030 (USD MILLION)

TABLE 66 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 67 DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 68 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 69 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 70 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 71 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 72 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 73 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 74 DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY

REGION, 2023–2030 (USD MILLION)

TABLE 75 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 76 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 77 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 78 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 79 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY REGION, 2023–2030 (USD MILLION)

TABLE 80 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 81 DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION)

TABLE 82 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 83 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 84 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 85 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 86 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION)

TABLE 87 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 88 DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)

TABLE 89 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 90 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 91 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 92 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 93 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION)

TABLE 94 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 95 DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION)

TABLE 96 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 97 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 98 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 99 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 100 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION)

TABLE 101 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 102 DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 103 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 104 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 105 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 106 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 107 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 108 DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY REGION, 2023–2030 (USD MILLION)

TABLE 109 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 110 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY

CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 111 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 112 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 113 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY REGION, 2023–2030 (USD MILLION)

TABLE 114 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 115 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY REGION, 2023–2030 (USD MILLION)

TABLE 116 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 117 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 118 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 119 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 120 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY REGION, 2023–2030 (USD MILLION)

TABLE 121 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 122 DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY REGION, 2023–2030 (USD MILLION)

TABLE 123 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 124 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 125 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 126 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 127 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY REGION, 2023–2030 (USD MILLION)

TABLE 128 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 129 DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 130 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 131 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 132 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 133 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 134 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 135 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 136 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)

TABLE 137 DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 138 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 139 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 140 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 141 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 142 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 143 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 144 DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 145 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 146 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 147 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 148 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 149 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR

TARGET VALIDATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 150 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 151 DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 152 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 153 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 154 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 155 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 156 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 157 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 158 DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 159 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 160 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 161 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 162 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 163 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 164 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 165 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 166 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 167 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 168 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 169 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 170 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 171 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 172 DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)

TABLE 173 DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)

TABLE 174 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 175 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 176 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 177 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 178 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)

TABLE 179 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 180 DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)

TABLE 181 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 182 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 183 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 184 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 185 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)

TABLE 186 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 187 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION)

TABLE 188 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR

CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 189 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 190 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 191 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 192 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION)

TABLE 193 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 194 DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL  
DISEASES, BY REGION, 2023–2030 (USD MILLION)

TABLE 195 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 196 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 197 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 198 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 199 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION)

TABLE 200 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 201 DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE &  
METABOLIC DISORDERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 202 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD  
MILLION)

TABLE 203 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD  
MILLION)

TABLE 204 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD  
MILLION)

TABLE 205 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD  
MILLION)

TABLE 206 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 207 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 208 DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 209 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 210 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 211 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 212 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 213 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 214 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 215 DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)

TABLE 216 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 217 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 218 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 219 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 220 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)

TABLE 221 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 222 DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 223 DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 224 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR

PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030  
(USD MILLION)

TABLE 225 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030  
(USD MILLION)

TABLE 226 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030  
(USD MILLION)

TABLE 227 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030  
(USD MILLION)

TABLE 228 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030  
(USD MILLION)

TABLE 229 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030  
(USD MILLION)

TABLE 230 DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC &  
RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)

TABLE 231 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 232 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 233 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 234 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 235 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)

TABLE 236 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 237 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT  
RESEARCH ORGANIZATIONS (CRO), BY REGION, 2023–2030 (USD MILLION)

TABLE 238 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
CONTRACT RESEARCH ORGANIZATIONS (CRO), BY COUNTRY, 2023–2030  
(USD MILLION)

TABLE 239 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR  
CONTRACT RESEARCH ORGANIZATIONS (CRO), BY COUNTRY, 2023–2030  
(USD MILLION)

TABLE 240 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CRO), BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 241 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CRO), BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 242 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CRO), BY REGION, 2023–2030 (USD MILLION)

TABLE 243 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CRO), BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 244 DRUG DISCOVERY TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 245 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 246 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 247 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 248 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 249 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)

TABLE 250 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)

TABLE 251 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 252 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 253 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 254 US: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 255 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)

TABLE 256 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC

AREA, 2023–2030 (USD MILLION)

TABLE 257 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 258 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 259 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 260 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 261 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)

TABLE 262 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)

TABLE 263 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 264 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 265 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 266 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 267 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 268 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)

TABLE 269 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)

TABLE 270 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 271 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 272 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 273 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 274 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY

PROCESS, 2023–2030 (USD MILLION)

TABLE 275 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)

TABLE 276 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 277 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 278 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 279 UK: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 280 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)

TABLE 281 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)

TABLE 282 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 283 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION)

TABLE 284 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 285 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 286 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION)

TABLE 287 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)

TABLE 288 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION)

## List Of Figures

### LIST OF FIGURES

FIGURE 1 DRUG DISCOVERY TECHNOLOGIES MARKET SEGMENTATION AND REGIONS CONSIDERED

FIGURE 2 DRUG DISCOVERY TECHNOLOGIES MARKET: YEARS CONSIDERED

FIGURE 3 MARKET SCENARIO

FIGURE 4 GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET, 2023–2030

FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY TECHNOLOGIES MARKET, 2022–2025

FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF DRUG DISCOVERY TECHNOLOGIES MARKET

FIGURE 7 HIGH-GROWTH SEGMENTS IN DRUG DISCOVERY TECHNOLOGIES MARKET, 2025–2030

FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN DRUG DISCOVERY TECHNOLOGIES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD

FIGURE 9 REAGENTS & CONSUMABLES SEGMENT AND US LED NORTH AMERICAN MARKET IN 2024

FIGURE 10 ASIA PACIFIC IS LIKELY TO BE FASTEST-GROWING MARKET IN DRUG DISCOVERY TECHNOLOGIES MARKET DURING FORECAST PERIOD

FIGURE 11 REAGENTS & CONSUMABLES TO DOMINATE MARKET DURING FORECAST PERIOD

FIGURE 12 DRUG DISCOVERY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 13 DRUG DISCOVERY TECHNOLOGIES MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 14 GROWTH OF GLOBAL GDP FROM 2020 TO 2024, WITH FORECASTS UNTIL 2030

FIGURE 15 DRUG DISCOVERY TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS

FIGURE 16 DRUG DISCOVERY TECHNOLOGIES MARKET: ECOSYSTEM ANALYSIS

FIGURE 17 AVERAGE SELLING PRICE OF INSTRUMENTS, BY KEY PLAYER, 2024 (USD)

FIGURE 18 AVERAGE SELLING PRICE OF CONSUMABLES, BY KEY PLAYER, 2024 (USD)

FIGURE 19 AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2024 (USD MILLION)

FIGURE 20 AVERAGE SELLING PRICE OF CONSUMABLES, BY REGION, 2024

(USD MILLION)

FIGURE 21 DRUG DISCOVERY TECHNOLOGIES MARKET:

TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

FIGURE 22 DRUG DISCOVERY TECHNOLOGIES MARKET: INVESTMENT AND  
FUNDING SCENARIO, 2022–2025 (USD MILLION)

FIGURE 23 PATENT APPLICATIONS IN DRUG DISCOVERY TECHNOLOGIES  
MARKET, JANUARY 2014–DECEMBER 2024

FIGURE 24 IMPACT OF AI/GEN AI ON DRUG DISCOVERY TECHNOLOGIES  
MARKET

FIGURE 25 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY  
PRODUCT

FIGURE 26 KEY BUYING CRITERIA, BY END USER

FIGURE 27 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET  
SNAPSHOT

FIGURE 28 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET  
SNAPSHOT

FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2024

FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024

FIGURE 31 DRUG DISCOVERY TECHNOLOGIES MARKET: BRAND/PRODUCT  
COMPARISON

FIGURE 32 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY  
EVALUATION MATRIX (KEY PLAYERS), 2024

FIGURE 33 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY FOOTPRINT

FIGURE 34 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY  
EVALUATION MATRIX (STARTUPS/SMES), 2024

FIGURE 35 EV/EBITDA OF KEY VENDORS

FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK  
BETA OF KEY VENDORS

FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)

FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2024)

FIGURE 39 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)

FIGURE 40 REVVITY: COMPANY SNAPSHOT (2024)

FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2024)

FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2024)

FIGURE 43 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024)

FIGURE 44 BRUKER: COMPANY SNAPSHOT (2024)

FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2024)

FIGURE 46 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024)

FIGURE 47 TECAN TRADING AG: COMPANY SNAPSHOT (2024)

- FIGURE 48 TAKARA BIO INC.: COMPANY SNAPSHOT (2024)
- FIGURE 49 CORNING INCORPORATED: COMPANY SNAPSHOT (2024)
- FIGURE 50 PACBIO: COMPANY SNAPSHOT (2024)
- FIGURE 51 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2024)
- FIGURE 52 WATERS CORPORATION: COMPANY SNAPSHOT (2024)
- FIGURE 53 SARTORIUS AG: COMPANY SNAPSHOT (2024)
- FIGURE 54 BD: COMPANY SNAPSHOT (2024)
- FIGURE 55 EPPENDORF SE: COMPANY SNAPSHOT (2024)
- FIGURE 56 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2024)
- FIGURE 57 STANDARD BIOTOOLS: COMPANY SNAPSHOT (2024)
- FIGURE 58 JEOL LTD.: COMPANY SNAPSHOT
- FIGURE 59 BIOM?RIEUX: COMPANY SNAPSHOT (2024)
- FIGURE 60 GREINER AG: COMPANY SNAPSHOT (2024)
- FIGURE 61 PORVAIR: COMPANY SNAPSHOT (2024)
- FIGURE 62 DRUG DISCOVERY TECHNOLOGIES MARKET: RESEARCH DESIGN
- FIGURE 63 DRUG DISCOVERY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARIES
- FIGURE 64 DRUG DISCOVERY TECHNOLOGIES MARKET: INSIGHTS FROM PRIMARIES
- FIGURE 65 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2024)
- FIGURE 66 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE ANALYSIS (2024)
- FIGURE 67 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
- FIGURE 68 DRUG DISCOVERY TECHNOLOGIES BASE NUMBER CALCULATION (SUPPLY-SIDE ANALYSIS), 2024
- FIGURE 69 DRUG DISCOVERY TECHNOLOGIES MARKET: CAGR PROJECTIONS
- FIGURE 70 DRUG DISCOVERY TECHNOLOGIES MARKET: DATA TRIANGULATION

## I would like to order

Product name: Drug Discovery Technologies Market by Product (Instruments, Reagents, Software), Technology (HTS, NGS, PCR, AI-based, Lab-on-chip), Process (Target Identification, Validation, Lead Optimization), Therapeutic Area (Oncology, CVD) - Global Forecast to 2030

Product link: <https://marketpublishers.com/r/DF4E212B304FEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DF4E212B304FEN.html>